The Ukrainian pharmaceutical company "Biopharma" has completed clinical trials of the drug "Bioven" for the treatment of pneumonia caused by the SARS-CoV-2 virus.
About this on his page in Facebook said the chairman of the company's board of directors, Konstantin Efimenko.
"Biopharma" completed clinical trials of our drug "Bioven» (immunoglobulin). Clinical studies started in May, 66 patients with a severe course of the disease were randomized, 9 bases were involved in the study. The investigation was completed in October," he wrote.
According to Efimenko, the use of "Bioven" in the complex therapy of pneumonia caused by SARS-CoV-2-Covid19, in comparison with standard therapy, makes it possible to achieve statistically significant advantages. In particular, the reduction of lethality — four times (from 23,6% to 6,25%), the reduction of the average time to improvement — from 9 to 5 days, the reduction of the time required for hospitalization in hospital conditions — by 3-5 days.
The head of the company noted that 18 clinical trials of immunoglobulin are ongoing in the world today. All of them were started by global international companies, mainly in the USA and Western Europe, however, "Biopharma" is the first company to start clinical research and the first to complete it.
According to Efimenko, yesterday "Bioven" was included in the protocol for the treatment of COVID-19.
